التفاصيل البيبلوغرافية
| العنوان: |
A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia. |
| المؤلفون: |
Yin, Jia, Wan, Chao-Ling, Zhang, Ling, Zhang, Hao, Bai, Lian, Zhou, Hai-Xia, Xu, Ming-Zhu, Chen, Li-Yun, Qian, Chong-Sheng, Qiu, Hui-Ying, Chen, Su-Ning, Tang, Xiao-Wen, Wu, De-Pei, Zhang, Yan-Ming, Sun, Ai-Ning, Xue, Sheng-Li |
| المصدر: |
Frontiers in Oncology; 9/3/2021, Vol. 12, p1-13, 13p |
| مصطلحات موضوعية: |
ACUTE myeloid leukemia, GRANULOCYTE-colony stimulating factor, SOFT tissue infections, DECITABINE, EPIGENETICS |
| مستخلص: |
Objective: To explore the role of chidamide, decitabine plus priming regimen in the salvage treatment of relapsed/refractory acute myeloid leukemia. Methods: A clinical trial was conducted in relapsed/refractory acute myeloid leukemia patients using chidamide, decitabine, cytarabine, idarubicin, and granulocyte-colony stimulating factor, termed CDIAG, a double epigenetic priming regimen. Results: Thirty-five patients were recruited. Three patients received 2 treatment cycles. In 32 evaluable patients and 35 treatment courses, the completed remission rate (CRR) was 42.9%. The median OS time was 11.7 months. The median OS times of responders were 18.4 months, while those of nonresponders were 7.4 months (P = 0.015). The presence of RUNX1 mutations was associated with a high CRR but a short 2-year OS (P = 0.023) and PFS (P = 0.018) due to relapse after treatment. The presence of IDH mutations had no effect on the remission rate (80.0% vs. 73.3%), but showed a better OS (2-year OS rate: 100.0% vs. 28.9%). Grade 3/4 nonhematological adverse events included pneumonia, hematosepsis, febrile neutropenia, skin and soft tissue infection and others. Conclusion: The double epigenetic priming regimen (CDIAG regimen) showed considerably good antileukemia activity in these patients. Adverse events were acceptable according to previous experience. The study was registered as a clinical trial. Clinical Trial Registration: https://clinicaltrials.govTest/ , identifier:NCT03985007 [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder